Mohamed M. Salama

Dr. Mohamed M. Salama

Delta University for Science and Technology, Al Manşūrah, Ad Daqahlīyah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2024 in The FASEB Journal
Verified
Journal Article
Open access
SIMONA CAVALUSIMONA CAVALU
SIMONA CAVALU
AAAmir Abdelhamid
Amir Abdelhamid
Sameh SaberSameh Saber
Sameh Saber
Elsayed Abdelhadi Hassan ElmorsyElsayed Abdelhadi Hassan Elmorsy
Elsayed Abdelhadi Hassan Elmorsy
Rabab S. HamadRabab S. Hamad
Rabab S. Hamad
Mohamed M. SalamaMohamed M. Salama
Mohamed M. Salama
The cell cycle is tightly regulated to ensure controlled cell proliferation. Dysregulation of the cell cycle machinery is a hallmark of cancer that leads to unchecked growth. This review comprehensively analyzes key molecular regulators of the cell cycle and how they contribute to carcinogenesis when mutated or overexpressed. It focuses on cyclins, cyclin‐dependent kinases (CDKs), CDK inhibitors, checkpoint kinases, and mitotic regulators as therapeutic targets. Promising strategies include CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib for breast cancer treatment. Other possible targets include the anaphase‐promoting complex/cyclosome (APC/C), Skp2, p21, and aurora kinase inhibitors. However, challenges with resistance have limited clinical successes so far. Future efforts should focus on combinatorial therapies, next‐generation inhibitors, and biomarkers for patient selection. Targeting the cell cycle holds promise but further optimization is necessary to fully exploit it as an anti‐cancer strategy across diverse malignancies.

31 July 2019 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
Sameh SaberSameh Saber
Sameh Saber
AKAhmed E. Khodir
Ahmed E. Khodir
WSWafaa E. Soliman
Wafaa E. Soliman
Mohamed M. SalamaMohamed M. Salama
Mohamed M. Salama
WAWalied S. Abdo
Walied S. Abdo
AEAbdelrahman S. Eldin
Abdelrahman S. Eldin

7 July 2022 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
Mohamed M. SalamaMohamed M. Salama
Mohamed M. Salama
RZRanda Zaghloul
Randa Zaghloul
RKRania khalil
Rania khalil
MEMamdouh M. El-Shishtawy
Mamdouh M. El-Shishtawy
Sitagliptin (STG) is a highly selective dipeptidyl peptidase-4 inhibitor recently used in the treatment of type 2 diabetes. The current study aimed to investigate the anti-neoplastic effect of STG alone and in combination with Doxorubicin (Dox), a known chemotherapeutic agent but with ominous side effects. After intramuscular inoculation of 2 × 106 Ehrlich tumor cells, Female Swiss mice were divided into tumor-bearing control, STG-treated, Dox-treated, and a combination of STG and Dox-treated groups. The results showed a significant reduction in the tumor growth of the treated animals in comparison with those of the positive control group with a more prominent effect in the co-treated group. Where, the anti-proliferative and apoptotic effect of STG, and its chemo-sensitizing ability, when used in combination with Dox, was mediated by modulation of oxidative stress (MDA and GSH), attenuation of tumor inflammation (IL-6 and IL-1β), and angiogenesis (VEGF), suppressing proliferation (β-catenin and cyclin-D1) and enhancement of apoptosis (survivin, p53, caspase 3). Thus, in conclusion, STG as adjunctive therapy for Dox could be a strategy for the treatment of breast cancer patients, by their ability in hindering cell proliferation and minimizing the associated oxidative and inflammatory adverse reactions.

30 September 2018 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
Mohamed M. SalamaMohamed M. Salama
Mohamed M. Salama
MNManal M. Nomir
Manal M. Nomir
MFMaryan Waheeb Fahmi
Maryan Waheeb Fahmi
AEAmal M. El-Gayar
Amal M. El-Gayar
MEMamdouh M. El-Shishtawy
Mamdouh M. El-Shishtawy
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide. In an attempt to understand some potential mechanisms of persistence and oncogenicity of Hepatitis C virus (HCV)-related HCC, microfibrillar-associated protein 4 (MFAP4), fibrotic indices and oxidative status biomarkers were assessed in the sera of 50 patients with HCV-associated HCC, 25 patients with HCV-related liver cirrhosis and 15 healthy individuals. Serum oxidized Coenzyme Q10 (CoQ10) and malondialdehyde showed significant elevation in HCC patients compared to the control group (p < 0.001), as well as cirrhotic patients (p < 0.05 and p < 0.001, respectively), while serum glutathione content and superoxide dismutase activity were significantly decreased in HCC patients compared to the control group (p < 0.001). Serum MFAP4, aspartate aminotransferase to platelet ratio index (APRI), fibrosis index based on the 4 factors (FIB-4) and Forns index showed significant increase in HCC patients compared to the control group (p < 0.001), while only APRI and FIB-4 were significantly different between HCC and cirrhotic patients (p < 0.05), with a sensitivity of 86% and 92%, respectively, at cut off ≥0.7 for APRI and ≥1.57 for FIB-4. Therefore, increasing oxidative stress and fibrosis might mediate HCV induced cirrhosis and HCC. APRI and FIB-4 may be used as a simple non-expensive formula for the screening of HCC rather than MFAP4.

28 April 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Open access
PDF file
Mohamed M. SalamaMohamed M. Salama
Mohamed M. Salama
RZRanda Zaghloul
Randa Zaghloul
RKRania khalil
Rania khalil
MEMamdouh M. El-Shishtawy
Mamdouh M. El-Shishtawy
Natural bioactive compounds with anti-neoplastic effects, such as celastrol (CLS), have attracted considerable interest in recent years. The present study aimed to investigate the effect of CLS on wnt/β-catenin signaling, and its potential combination with doxorubicin (Dox) to enhance chemotherapeutic effects. After intramuscular inoculation of Ehrlich tumor cells, tumor-bearing mice received CLS (2 mg/kg, i.p), Dox (5 mg/kg, once/week, i.p), and their combination for 21 days. Treatment with CLS showed showing antioxidant and anti-inflammatory, as evidenced by a significant increase in glutathione content and a significant decrease in the malondialdehyde, interleukin 6, and interleukin 1β concentrations. CLS also inhibited VEGF-mediated angiogenesis. The current study revealed that CLS downregulated β‐catenin gene expression with subsequent downstream target genes, such as cyclin-D1, and survivin, which dampens tumor cell proliferation and triggers cell cycle arrest as well as induces apoptosis as indicated by the increased expression of p53, caspase‐3. The current study concludes that CLS exerted its anti-neoplastic activity by suppressing the wnt/β-catenin signaling pathway, and opens a new perspective for combining CLS with Dox to enhance its chemotherapeutic effects and reduce the oxidative imbalance and inflammatory responses associated with Dox treatment.

14 December 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
HHHanan Hafila
Hanan Hafila
Mohamed M. SalamaMohamed M. Salama
Mohamed M. Salama
Editorial: Implication of oxidative, inflammatory, apoptotic and autophagy pathways in colitis